What question did this study set out to answer?

To assess the efficacy, safety, and quality-of-life impacts of a structured weight management program for outpatients taking olanzapine for schizophrenia or schizoaffective disorder.

April 15, 2006The Journal of Clinical Psychiatry

Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients With Schizophrenia or Schizoaffective Disorder

View Full Paper

Ask AI

Bookmark

Authors

JKJun Soo Kwon JCJung‐Seok Choi WBWon-Myoung Bahk

Discussion

Member takes

Overview

Randomized trial demonstrates significant weight and BMI reduction in olanzapine-treated patients, indicating structured lifestyle interventions mitigate antipsychotic-induced weight gain.

Key Points

To assess the efficacy, safety, and quality-of-life impacts of a structured weight management program for outpatients taking olanzapine for schizophrenia or schizoaffective disorder.
A 12-week, randomized, multicenter trial enrolled 48 outpatients receiving olanzapine for schizophrenia or schizoaffective disorder.
Participants were randomly assigned to either olanzapine plus a structured weight management program (N=33) or standard outpatient olanzapine care as controls (N=15).
Body weight, body mass index (BMI), safety measures (vital signs, psychiatric symptoms, laboratory tests), and quality-of-life metrics were tracked through study completion.
Patients in the intervention group had significantly greater reductions in weight (-3.94 ± 3.63 kg vs. -1.48 ± 1.88 kg, p = .006) and BMI (-1.50 ± 1.34 vs. -0.59 ± 0.73, p = .007) than controls, with separation emerging at week 8 (p = .040).
Safety outcomes showed no significant differences between arms, including changes in the low-density to high-density lipoprotein ratio (-0.19 vs. -0.04, p = .556).
Physical health quality-of-life scores showed a trend toward improvement favoring the intervention group over controls (1.12 vs. -0.93, p = .067).

Cite This Study

Kwon et al. (2006) studied this question.

synapsesocial.com/papers/6aa897f06d30d9da665cc2ed https://doi.org/10.4088/jcp.v67n0405

View Full Paper

Ask AI

Bookmark

April 15, 2006The Journal of Clinical Psychiatry

Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients With Schizophrenia or Schizoaffective Disorder

View Full Paper

Ask AI

Bookmark

Authors

JKJun Soo Kwon JCJung‐Seok Choi WBWon-Myoung Bahk

Discussion

Member takes

Overview

Randomized trial demonstrates significant weight and BMI reduction in olanzapine-treated patients, indicating structured lifestyle interventions mitigate antipsychotic-induced weight gain.

Key Points

To assess the efficacy, safety, and quality-of-life impacts of a structured weight management program for outpatients taking olanzapine for schizophrenia or schizoaffective disorder.
A 12-week, randomized, multicenter trial enrolled 48 outpatients receiving olanzapine for schizophrenia or schizoaffective disorder.
Participants were randomly assigned to either olanzapine plus a structured weight management program (N=33) or standard outpatient olanzapine care as controls (N=15).
Body weight, body mass index (BMI), safety measures (vital signs, psychiatric symptoms, laboratory tests), and quality-of-life metrics were tracked through study completion.
Patients in the intervention group had significantly greater reductions in weight (-3.94 ± 3.63 kg vs. -1.48 ± 1.88 kg, p = .006) and BMI (-1.50 ± 1.34 vs. -0.59 ± 0.73, p = .007) than controls, with separation emerging at week 8 (p = .040).
Safety outcomes showed no significant differences between arms, including changes in the low-density to high-density lipoprotein ratio (-0.19 vs. -0.04, p = .556).
Physical health quality-of-life scores showed a trend toward improvement favoring the intervention group over controls (1.12 vs. -0.93, p = .067).

Cite This Study

Kwon et al. (2006) studied this question.

synapsesocial.com/papers/6aa897f06d30d9da665cc2ed https://doi.org/10.4088/jcp.v67n0405

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark